Industry trackers report 23 distinct base‑editing programs have entered the clinic, with more than half producing initial clinical readouts showing consistent signals of activity. The landscape spans in vivo and ex vivo approaches targeting monogenic and somatic disease indications. Early-stage data suggest on‑target editing and preliminary efficacy in several programs, bringing base editing from preclinical promise toward tangible clinical validation. The cluster of readouts is sharpening the technology’s development profile, helping investors and developers calibrate expectations for safety signals, delivery platforms, and editing windows. With multiple modalities and delivery chemistries in play, the field is beginning to identify shared operational and regulatory challenges — including off‑target assessment, durability of edit, and scalable manufacturing for gene‑editing therapeutics. Regulators and sponsors will use these early datasets to define clinical assays and long‑term monitoring. The cumulative clinical experience is now informing design choices for next‑generation editors and multi‑patient ‘n‑of‑many’ strategies that aim to broaden the applicability of base editing across patient populations.